Although the global economy continued to recover in 2010, biotech companies in the traditional enters of Australia, Canada, Europe and the United States each had a record-breaking year. According to Ernst & Young (ey.com), companies in these markets reported an aggregate net profit of $4.7 billion in 2010, a 30% increase compared to 2009.
The following information is included for the top 50 biotechnology companies (which were determined based on their healthcare revenue generated during 2010):
- Each products’ chemical or substance composition, intended indication, clinical status, region of development, and developer/marketer
- Pipeline status details preclinical development, Phase I, Phase II, Phase III, and awaiting approval
- Region of development includes the U.S., Europe, and Japan
- Select 2010 and 2009 financial data such as revenue, net income, earnings per share, and R&D expenditure
An overview highlighting the top 10 biotech companies and some of their most-promising products.